Sequential dual-target tDCS for tobacco use disorder: A longitudinal pilot case series targeting craving and inhibitory control [0.03%]
针对烟草使用障碍的序贯双靶点经颅直流电刺激：一项侧重于渴求和抑制控制的纵向初步病例系列研究
Thiago P Fernandes,Givago S Souza,Natanael A Santos
Thiago P Fernandes
Background: Transcranial direct current stimulation (tDCS) is increasingly explored as an adjunctive intervention for Tobacco Use Disorder (TUD). Studies typically employ single-site stimulation protocols, and reported ef...
Comparative outcomes of opioid withdrawal management strategy in patients with injection-related bacteremia [0.03%]
注射相关菌血症患者的阿片类药物脱毒管理策略的比较结果
Samuel Handy,Timothy Garton,Ilan Schwell et al.
Samuel Handy et al.
Hospitalized patients with opioid use disorder present unique clinical challenges, including higher rates of patient-directed discharge (PDD), incomplete treatment courses, and frequent readmissions. To compare outcomes in hospitalized pati...
Wearable physiological signals and relapse status during smoking cessation: a pilot study [0.03%]
可穿戴生理信号在戒烟过程中的应用及复吸状态的试点研究
Irina I Shoshina,Natanael A Santos,Thiago P Fernandes et al.
Irina I Shoshina et al.
Background: Smoking cessation is often assessed using clinical and self-report measures that may not capture autonomic changes. Wearables allow continuous monitoring. ...
Admitting powerlessness empowers recovery from substance use disorder: a conceptual model [0.03%]
认输才能成功：成瘾行为戒断的动力模型
Gila Chen
Gila Chen
Some individuals use substances to cope with their post-traumatic stress disorder symptoms. The emotional, behavioral, and spiritual experience of both their post-traumatic stress disorder and substance use disorder is manifested in a sense...
Darrin Mangiacarne
Darrin Mangiacarne
Reconceptualizing addiction as metabolic-arousal dysregulation: a structured theory-synthesis across neurobiological, physiological and psychological domains [0.03%]
从神经生物学、生理学和心理学的角度重新定义上瘾为代谢唤醒失调：一种结构化的理论综合方法
Christopher Lomas
Christopher Lomas
Background: Prevailing models of addiction emphasize reward dysregulation, stress neuroadaptation and impaired executive control, but typically treat metabolic disturbance as secondary. Convergent evidence across neuroima...
Association of GLP-1 receptor agonist use with long-term outcomes in patients with opioid use disorder [0.03%]
GLP-1受体激动剂与阿片类药物使用障碍患者长期预后之间的相关性
Dhairya A Lakhani,Wanhong Zheng
Dhairya A Lakhani
Opioid use disorder (OUD) is a major public health challenge with high overdose mortality and healthcare utilization. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer cardiometabolic and neurobiological benefits, including modulat...
Cannabis Use Disorder as a disorder of motivational dysregulation: a systematic review of clinical, neurocognitive, and treatment evidence [0.03%]
动机失调视角下的大麻使用障碍：临床、神经认知及治疗证据的系统回顾研究
Sidharth Mishra,Sayali Mishra,Ashwini Rajmohan et al.
Sidharth Mishra et al.
This systematic review evaluated whether CUD can be coherently reconceptualized as a disorder of motivational dysregulation by synthesizing clinical, neurocognitive, and treatment-related evidence published over the last 10 years. A systema...
Challenges of AI-generated stigmatizing language regarding substance use disorders [0.03%]
关于物质使用障碍的AI生成污名化语言的挑战
Vincent Kennedy,Andrew Francis
Vincent Kennedy
Stigmatizing language describing substance use behaviors in clinical documentation and in patient education materials can harm patients and their families. Recent literature has discouraged the use of stigmatizing language in treatment sett...
Underutilization of PETH testing among patients with MASLD - retrospective, single-center evaluation of the frequency and results of phosphatidylethanol testing among patients diagnosed with metabolic dysfunction-associated liver disease [0.03%]
MASLD患者中PETH检测利用不足的回顾性、单中心评估：代谢功能障碍相关肝病患者磷脂乙醇检测频率和结果的回顾性、单中心评估
Annabel McLaughlin,Margot Manning,Michelle Lai et al.
Annabel McLaughlin et al.
Alcohol may confound or complicate diagnosis of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Though phosphatidylethanol (PETH) testing is widely available, its use among patients with MASLD has not been well established...